长春新碱输注治疗难治性妇科恶性肿瘤

Vincristine infusion in refractory gynecologic malignancies.

作者信息

Jackson D V, Jobson V W, Homesley H D, Welander C, Hire E A, Pavy M D, Votaw M L, Richards F, Muss H B

出版信息

Gynecol Oncol. 1986 Oct;25(2):212-6. doi: 10.1016/0090-8258(86)90101-0.

Abstract

Prolonged intravenous infusion of vincristine was evaluated in 26 patients with advanced, refractory gynecologic malignancies. Most patients (88%) had progressive disease following treatment with one or more chemotherapeutic agents. Treatment consisted of a 0.5 mg intravenous bolus injection followed immediately by continuous infusion of 0.25-0.50 mg/m2 vincristine given daily for 5 days. There were no objective responses observed among 14 patients with carcinoma of the cervix, 7 patients with carcinoma of the ovary, or 5 patients with carcinoma of the endometrium. Toxicity was mild when present and consisted of paresthesias and myalgias. Vincristine infusion appears to be a well-tolerated but ineffective treatment for refractory gynecologic malignancies.

摘要

对26例晚期难治性妇科恶性肿瘤患者进行了长春新碱长时间静脉输注的评估。大多数患者（88%）在接受一种或多种化疗药物治疗后病情仍进展。治疗方案为静脉推注0.5 mg，随后立即每日持续输注0.25 - 0.50 mg/m²长春新碱，共5天。14例宫颈癌患者、7例卵巢癌患者和5例子宫内膜癌患者中均未观察到客观缓解。毒性反应若出现则较轻，包括感觉异常和肌痛。长春新碱输注对于难治性妇科恶性肿瘤似乎是一种耐受性良好但无效的治疗方法。